 |
31 Diseases |  |
34 Trials |
|
34 Trials |  |
1690 News |  |
| «12...78910111213141516171819» |
- | Kanarb (fimasartan) - Boryung Group, R / Pharm
New P1 trial: A Clinical Trial to Evaluate Pharmacokinetic Interactions and Safety Between Fimasartan and Linagliptin in Healthy Male Volunteers (clinicaltrials.gov) - Aug 15, 2017
P1, N=37, Active, not recruiting, Sponsor: Boryung Pharmaceutical Co., Ltd
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial primary completion date: DYDA2: Effects of Linagliptin on Left Ventricular Myocardial DYsfunction in Patients With Type 2 DiAbetes Mellitus and Concentric Left Ventricular Geometry (clinicaltrials.gov) - Aug 8, 2017
P3, N=186, Recruiting, Sponsor: Heart Care Foundation
Trial primary completion date: Jul 2017 --> Dec 2017
- | Trial primary completion date: Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments. (clinicaltrials.gov) - Aug 2, 2017
P=N/A, N=50, Recruiting, Sponsor: Erasme University Hospital
Trial primary completion date: Jul 2017 --> Dec 2017 Trial primary completion date: Oct 2016 --> Jul 2019
- ||| Zafatek (trelagliptin) / Takeda
Enrollment closed: Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Jul 31, 2017
P4, N=211, Active, not recruiting, Sponsor: Takeda
Trial primary completion date: Oct 2016 --> Jul 2019 Recruiting --> Active, not recruiting
- ||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
Trial completion, Enrollment change, Trial primary completion date: A Regulatory Requirement Non Interventional Study to Monitor Safety and Effectiveness of Trajenta Duo in Type 2 Diabetes Patients in Korea (clinicaltrials.gov) - Jul 23, 2017
P=N/A, N=724, Completed, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting Recruiting --> Completed | N=600 --> 724 | Trial primary completion date: Sep 2017 --> May 2017
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
New P4 trial, Monotherapy: Effects of Sequential Treatment Based on Lina/MET After Short-term Intensive Insulin in Newly Diagnosed Type 2 Diabetes (clinicaltrials.gov) - Jun 20, 2017
P4, N=448, Not yet recruiting, Sponsor: Sun Yat-sen University
- |||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial completion, Trial primary completion date: Linagliptin as Add on to Basal Insulin in the Elderly (clinicaltrials.gov) - May 30, 2017
P4, N=302, Completed, Sponsor: Boehringer Ingelheim
Recruiting --> Completed | N=600 --> 724 | Trial primary completion date: Sep 2017 --> May 2017 Active, not recruiting --> Completed | Trial primary completion date: Oct 2016 --> Apr 2017
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial completion: ADA Linagliptin in Long Term Care (clinicaltrials.gov) - Apr 17, 2017
P4, N=147, Completed, Sponsor: Emory University
Active, not recruiting --> Completed | Trial primary completion date: Oct 2016 --> Apr 2017 Recruiting --> Completed
- | Victoza (liraglutide) / Novo Nordisk, Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Byetta (exenatide) / AstraZeneca
Trial completion: The Microvascular Function of GLP-1 and Its Analogues (clinicaltrials.gov) - Apr 13, 2017
P=N/A, N=63, Completed, Sponsor: Katarina Kos
Recruiting --> Completed Recruiting --> Completed
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial completion: Effects of Linagliptin on Endothelial Function (clinicaltrials.gov) - Mar 22, 2017
P4, N=42, Completed, Sponsor: Medical University of Graz
Recruiting --> Completed Active, not recruiting --> Completed
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial completion, Surgery: Linagliptin Inpatient Trial (clinicaltrials.gov) - Mar 10, 2017
P4, N=295, Completed, Sponsor: Emory University
Active, not recruiting --> Completed Recruiting --> Completed
- | Bariatric surgery: Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment (clinicaltrials.gov) - Mar 3, 2017
P4, N=40, Recruiting, Sponsor: Khoo Teck Puat Hospital
Recruiting --> Completed N=20 --> 40
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment change: PMS of Trazenta on the Long-term Use as Add-on Therapy (clinicaltrials.gov) - Feb 27, 2017
P=N/A, N=3640, Active, not recruiting, Sponsor: Boehringer Ingelheim
N=20 --> 40 N=3000 --> 3640
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment change: Long-term Daily Use of Trazenta (clinicaltrials.gov) - Feb 27, 2017
P=N/A, N=4554, Active, not recruiting, Sponsor: Boehringer Ingelheim
N=3000 --> 3640 N=3300 --> 4554
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial primary completion date: Long-term Daily Use of Trazenta (clinicaltrials.gov) - Feb 15, 2017
P=N/A, N=3300, Active, not recruiting, Sponsor: Boehringer Ingelheim
N=3300 --> 4554 Trial primary completion date: Jul 2017 --> Oct 2017
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
New P3 trial: Safety and Efficiency of Linagliptin (Trajenta) in the Setting of Internal Medicine Department (clinicaltrials.gov) - Feb 13, 2017
P3, N=60, Not yet recruiting, Sponsor: Rabin Medical Center
- | metformin / Generic mfg., Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
Journal: Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia. (Pubmed Central) - Feb 7, 2017
P4
Linagliptin/metformin combination in newly diagnosed T2D patients with marked hyperglycemia was well tolerated and elicited substantial improvements in glycemic control regardless of baseline HbA1c, age, BMI, renal function, or race. Thus, newly diagnosed, markedly hyperglycemic patients may be effectively treated by combinations of oral agents.
- |||| Zafatek (trelagliptin) / Takeda
Enrollment open: Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Feb 7, 2017
P4, N=240, Recruiting, Sponsor: Takeda
Thus, newly diagnosed, markedly hyperglycemic patients may be effectively treated by combinations of oral agents. Not yet recruiting --> Recruiting
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment change: Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin (clinicaltrials.gov) - Jan 30, 2017
P=N/A, N=99999, Recruiting, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting N=500000 --> 99999
- ||||| Zafatek (trelagliptin) / Takeda
New P4 trial: Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Jan 8, 2017
P4, N=240, Not yet recruiting, Sponsor: Takeda
- ||||| Tenelia (teneligliptin) / Daiichi Sankyo, Mitsubishi Tanabe
New P4 trial, Head-to-Head: TELIUS: Teneligliptin Versus Linagliptin in Diabetes Mellitus Type Two Patients (clinicaltrials.gov) - Jan 5, 2017
P4, N=164, Not yet recruiting, Sponsor: Handok Pharmaceuticals Co., Ltd.
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
New P4 trial: PRELLIM: Effect of Linagliptin + Metformin vs Metformin Alone in Patients With Prediabetes (clinicaltrials.gov) - Dec 28, 2016
P4, N=75, Recruiting, Sponsor: Universidad de Guanajuato
- |||||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment open, Combination therapy: Linagliptin Add-on to Insulin Background Therapy (clinicaltrials.gov) - Dec 5, 2016
P3, N=206, Recruiting, Sponsor: Boehringer Ingelheim
N=500000 --> 99999 Not yet recruiting --> Recruiting
- ||||| Sugarnon (evogliptin) - Dong / A
New P4 trial: Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes(EVERGREEN) (clinicaltrials.gov) - Nov 28, 2016
P4, N=200, Recruiting, Sponsor: Dong-A ST Co., Ltd.
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial primary completion date: Linagliptin in Schizophrenia Patients (clinicaltrials.gov) - Sep 26, 2016
P1, N=5, Suspended, Sponsor: Monash University
Not yet recruiting --> Recruiting Trial primary completion date: Jul 2016 --> Jul 2018
- ||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment closed: Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA) (clinicaltrials.gov) - Sep 21, 2016
P4, N=8300, Active, not recruiting, Sponsor: Boehringer Ingelheim
Trial primary completion date: Jul 2016 --> Jul 2018 Recruiting --> Active, not recruiting
- |||||||||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
New P3 trial, Combination therapy: Linagliptin Add-on to Insulin Background Therapy (clinicaltrials.gov) - Sep 13, 2016
P3, N=206, Not yet recruiting, Sponsor: Boehringer Ingelheim
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment closed, Trial primary completion date: Effects of Linagliptin on Endothelial Function (clinicaltrials.gov) - Aug 17, 2016
P4, N=42, Active, not recruiting, Sponsor: Medical University of Graz
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2016 --> Nov 2016
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
New P1 trial: Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany) (clinicaltrials.gov) - Aug 5, 2016
P1, N=24, Completed, Sponsor: Genuine Research Center, Egypt
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
New P3 trial: DYDA2: Effects of Linagliptin on Left Ventricular Myocardial DYsfunction in Patients With Type 2 DiAbetes Mellitus and Concentric Left Ventricular Geometry (clinicaltrials.gov) - Aug 2, 2016
P3, N=186, Recruiting, Sponsor: Heart Care Foundation
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial completion: The Effect of Linagliptin on Mitochondrial and Endothelial Function (clinicaltrials.gov) - Jul 23, 2016
P4, N=45, Completed, Sponsor: Beth Israel Deaconess Medical Center
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2016 --> Nov 2016 Recruiting --> Completed
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial suspension, Trial primary completion date: Linagliptin in Schizophrenia Patients (clinicaltrials.gov) - Jul 19, 2016
P1, N=5, Suspended, Sponsor: Monash University
Recruiting --> Completed Recruiting --> Suspended | Trial primary completion date: Oct 2016 --> Jul 2016
- |||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial primary completion date: CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes (clinicaltrials.gov) - Jun 22, 2016
P3, N=6115, Active, not recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Suspended | Trial primary completion date: Oct 2016 --> Jul 2016 Trial primary completion date: Sep 2018 --> Feb 2019
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Biomarker: RENALIS: Renal Effects of DPP-4 Inhibitor Linagliptin in Type 2 Diabetes (clinicaltrials.gov) - May 18, 2016
P4, N=48, Completed, Sponsor: VU University Medical Center
Trial primary completion date: Sep 2018 --> Feb 2019 Active, not recruiting --> Completed
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial completion, Monotherapy: Off taRget Effects of Linagliptin monothErapy on Arterial Stiffness in Early Diabetes (clinicaltrials.gov) - May 18, 2016
P3, N=45, Completed, Sponsor: dr. DJ Mulder
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial primary completion date: The Effect of LINAGLIPTIN on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects (clinicaltrials.gov) - May 12, 2016
P4, N=40, Recruiting, Sponsor: University at Buffalo
Active, not recruiting --> Completed Trial primary completion date: Feb 2016 --> Jul 2016
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial primary completion date: Effects of Linagliptin on Endothelial Function (clinicaltrials.gov) - May 4, 2016
P4, N=50, Recruiting, Sponsor: Medical University of Graz
Trial primary completion date: Feb 2016 --> Jul 2016 Trial primary completion date: Apr 2016 --> Jul 2016
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial completion, Enrollment change: Effects of Linagliptin on Active GLP-1 Concentrations in Subjects With Renal Impairment (clinicaltrials.gov) - May 3, 2016
P4, N=99, Completed, Sponsor: Profil Institut f
Trial primary completion date: Apr 2016 --> Jul 2016 Active, not recruiting --> Completed | N=30 --> 99
- ||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment closed: Linagliptin as Add on to Basal Insulin in the Elderly (clinicaltrials.gov) - May 2, 2016
P4, N=300, Active, not recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed | N=30 --> 99 Recruiting --> Active, not recruiting
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Biomarker: RENALIS: Renal Effects of DPP-4 Inhibitor Linagliptin in Type 2 Diabetes (clinicaltrials.gov) - Apr 22, 2016
P4, N=48, Active, not recruiting, Sponsor: VU University Medical Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial primary completion date: ADA Linagliptin in Long Term Care (clinicaltrials.gov) - Apr 13, 2016
P4, N=150, Recruiting, Sponsor: Emory University
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2016 --> Mar 2017
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
New trial: Incretin Axis in Type 1 Diabetes Mellitus (clinicaltrials.gov) - Apr 1, 2016
P=N/A, N=20, Recruiting, Sponsor: Postgraduate Institute of Medical Education and Research
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
New P4 trial: To compare gliclazide with linagliptin on the frequency of hypoglycaemia among patients with type II diabetes and chronic kidney disease stage 3b and 4. (EUDRACT) - Mar 31, 2016
P4, N=50, Ongoing, Sponsor: Imperial College London, Joint Research Compliance Office
- ||||||| Gemiglo (gemigliptin) / Sanofi, LG Chem
Trial completion: A Phase IIIb Study to Evaluate the Safety and Efficacy of Gemigliptin in Type 2 Diabetes Mellitus Patients With Moderate or Severe Renal Impairment(GUARD Study) (clinicaltrials.gov) - Mar 23, 2016
P3, N=132, Completed, Sponsor: LG Life Sciences
Trial primary completion date: Mar 2016 --> Mar 2017 Recruiting --> Completed
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment closed, Trial primary completion date: Effects of Linagliptin on Active GLP-1 Concentrations in Subjects With Renal Impairment (clinicaltrials.gov) - Feb 24, 2016
P4, N=30, Active, not recruiting, Sponsor: Profil Institut f
Recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2016 --> Jun 2016
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Clinical: Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology (clinicaltrials.gov) - Feb 24, 2016
P4, N=89, Completed, Sponsor: Profil Institut für Stoffwechselforschung GmbH
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2016 --> Jun 2016 Recruiting --> Completed | N=44 --> 89
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial completion, Enrollment change: Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes (clinicaltrials.gov) - Feb 17, 2016
P2, N=40, Completed, Sponsor: Boehringer Ingelheim
Recruiting --> Completed | N=44 --> 89 Active, not recruiting --> Completed | N=117 --> 40
- ||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment closed: Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes (clinicaltrials.gov) - Feb 11, 2016
P2, N=117, Active, not recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed | N=117 --> 40 Recruiting --> Active, not recruiting
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial primary completion date, Surgery: Linagliptin Inpatient Trial (clinicaltrials.gov) - Feb 2, 2016
P4, N=280, Recruiting, Sponsor: Emory University
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2015 --> Dec 2016
- ||||||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial completion: MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin (clinicaltrials.gov) - Dec 25, 2015
P3, N=360, Completed, Sponsor: Boehringer Ingelheim
Trial primary completion date: Dec 2015 --> Dec 2016 Active, not recruiting --> Completed